Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 26;11(6):589.
doi: 10.3390/genes11060589.

The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery

Virginie Scotet  1 , Carine L'Hostis  1 , Claude Férec  1   2
Affiliations
Review

The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery

Virginie Scotet et al. Genes (Basel). .

Abstract

Significant advances in the management of cystic fibrosis (CF) in recentdecades have dramatically changed the epidemiology and prognosis of this serious disease, which is no longer an exclusively pediatric disease. This paper aims to review the changes in the incidence and survival of CF and to assess the impact of the discovery of the responsible gene (the CFTR gene) on these changes. The incidence of CF appears to be decreasing in most countries andpatient survival, which can be monitored by various indicators, has improved substantially, with an estimated median age of survivalof approximately50 years today. Cloning of the CFTR gene 30 years ago and efforts to identify its many mutations have greatly improved the management of CF. Implementation of genetic screening policies hasenabled earlier diagnosis (via newborn screening), in addition to prevention within families or in the general population in some areas (via prenatal diagnosis, family testing or population carrier screening). In the past decade, in-depth knowledge of the molecular bases of CF has also enabled the emergenceof CFTR modulator therapies which have led to major clinical advances in the treatment of CF. All of these phenomena have contributed to changing the face of CF. The advent of targeted therapies has paved the way for precision medicine and is expected to further improve survival in the coming years.

Keywords: CFTR gene; CFTR modulators; cystic fibrosis; genotype-phenotype correlations; health policies; incidence; newborn screening; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Welsh M., Ramsey B.W., Accurso F.J., Cutting G.R. Cystic fibrosis. In: Scriver C.R., Beaudet A.L., Sly W.S., Valle D., Childs B., Vogelstein B., editors. The Metabolic and Molecular Basis of Inherited Disease. 8th ed. McGraw Hill; New York, NY, USA: 2001. pp. 5121–5188.
    1. Bell S.C., Mall M.A., Gutierrez H., Macek M., Madge M., Davies J.C., Burgel P.R., Tullis E., Castanos C., Castellani C., et al. The Future of Cystic Fibrosis Care: A Global Perspective. Lancet Respir. Med. 2020;8:65–124. doi: 10.1016/S2213-2600(19)30337-6. - DOI - PMC - PubMed
    1. Dodge J.A., Lewis P.A. Cystic fibrosis is no longer an important cause of childhood death in the UK. Arch. Dis. Child. 2005;90:547. - PMC - PubMed
    1. Fajac I., Burgel P.R. Demographic growth and targeted therapies: The changing face of cystic fibrosis. Rev. Mal. Respir. 2016;33:645–647. doi: 10.1016/j.rmr.2015.12.001. - DOI - PubMed
    1. Stephenson A.L., Stanojevic S., Sykes J., Burgel P.R. The changing epidemiology and demography of cystic fibrosis. Presse Med. 2017;46:e87–e95. doi: 10.1016/j.lpm.2017.04.012. - DOI - PubMed

Publication types

MeSH terms

Substances